This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment. For these reasons, it's important to develop flexible infusion regimens tailored to meet individual patient needs. Patient-centric strategies that promote shared decision-making and awareness of patient status not only promote medical efficacy but also enhance the overall patient experience. The authors of this report call attention for a need to shift toward more adaptable and individualized SCIG treatment plans for PAD patients whose needs may change over the long-term course of treatment.

Primary antibody deficiency (PAD) is a condition where the immune system doesn’t work properly, making it hard for the body to fight infections. To stay healthy, people with PAD need regular doses of a medication called immunoglobulin (IgG), which helps strengthen the immune system. This medication can be given in two main ways: through a vein (intravenously, or IVIG) or under the skin (subcutaneously, or SCIG). SCIG has some important benefits. It can be given at home, making it easier for patients to fit treatment into their daily lives. SCIG also causes fewer side effects compared to IVIG. Patients can choose when to take SCIG, making it more flexible and convenient. This article explains how doctors and patients can work together to make SCIG fit into each person’s lifestyle. Flexibility can make treatment less stressful and help patients stick to their treatment plan. One type of SCIG, called SCIG 16.5%, can be taken daily, weekly, every 2 weeks, or multiple times a week as long as the total monthly dose stays the same. Flexible ways to use SCIG are safe and effective and can help people manage their treatment leading to better health over time.

Department of Clinical Immunology and Allergology St Anne's University in Brno Faculty of Medicine Masaryk University Brno Czechia

Division of Basic and Clinical Immunology University of California Irvine CA USA

Division of Pediatric Immunology and Allergy School of Medicine University of California Los Angeles CA USA

Medical Affairs Midland Pediatrics Papillion NE USA

Medical Affairs Octapharma AG Vienna Austria

Medical Affairs Octapharma USA Inc Paramus NJ USA

Zobrazit více v PubMed

Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017. Mar;139(3S):S1–S46. doi: 10.1016/j.jaci.2016.09.023 PubMed DOI

Bayry J, Ahmed EA, Toscano-Rivero D, et al. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunol: In Pract. 2023;11(6):1688–1697. doi: 10.1016/j.jaip.2023.04.002 PubMed DOI

Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004. Jul;112(1):1–7. doi: 10.1057/rm.2009.17 PubMed DOI

Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009. Dec;158(Suppl 1):51–59. doi: 10.1111/j.1365-2249.2009.04027.x PubMed DOI PMC

Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277–287. doi: 10.2147/BTT.S25188 PubMed DOI PMC

Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: the European experience. Curr Opin Allergy Clin Immunol. 2013. Dec;13(6):623–629. doi: 10.1097/ACI.0000000000000013 PubMed DOI

Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–1192. doi: 10.1007/s10875-012-9720-1 PubMed DOI

Petersson C, Fust R, Hagstedt C, et al. “Experiences of the burden of treatment”-patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency. J Clin Nurs. 2018. Dec;27(23–24):4270–4278. doi: 10.1111/jocn.14580 PubMed DOI

Burton J, Murphy E, Riley P. Primary immunodeficiency disease: a model for case management of chronic diseases. Prof Case Manag. 2010. Jan;15(1):5–10, 12–4; quiz 15–6. doi: 10.1097/NCM.0b013e3181b5dec4 PubMed DOI

Isung J, Williams K, Isomura K, et al. Association of primary humoral immunodeficiencies with psychiatric disorders and suicidal behavior and the role of autoimmune diseases. JAMA Psychiatry. 2020. Nov 1;77(11):1147–1154. doi: 10.1001/jamapsychiatry.2020.1260 PubMed DOI PMC

Jones GL, Hajdukova EB, Hanna E, et al. It’s long-term, well it’s for life basically: understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders. Qual Res Med Healthcare. 2020;4(3):9564.

Jones GL, Vogt KS, Chambers D, et al. What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A systematic review. Front Immunol. 2018;9:1308. doi: 10.3389/fimmu.2018.01308 PubMed DOI PMC

Epland K, Suez D, Paris K. A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol. 2022. Sep 30;18(1):87. doi: 10.1186/s13223-022-00726-7 PubMed DOI PMC

Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21(2):105–116. doi: 10.2165/00063030-200721020-00005 PubMed DOI

Fu LW, Song C, Isaranuwatchai W, et al. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis. Ann Allergy Asthma Immunol. 2018. Feb;120(2):195–199. doi: 10.1016/j.anai.2017.11.002 PubMed DOI

Paris K, Wall LA. The treatment of primary immune deficiencies: lessons learned and future opportunities. Clin Rev Allergy Immunol. 2023;65(1):19–30. doi: 10.1007/s12016-022-08950-0 PubMed DOI PMC

Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012. Oct;130(4):951–7.e11. doi: 10.1016/j.jaci.2012.06.021 PubMed DOI

Mallick R, Solomon G, Bassett P, et al. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes. Allergy Asthma Clin Immunol. 2022. Dec 24;18(1):110. doi: 10.1186/s13223-022-00746-3 PubMed DOI PMC

Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004. Oct;114(4):936–942. doi: 10.1016/j.jaci.2004.06.053 PubMed DOI

Stein MR, Koterba A, Rodden L, et al. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med. 2011. Sep;123(5):186–193. doi: 10.3810/pgm.2011.09.2474 PubMed DOI

Fortier JC, Haltigan E, Cavero-Chavez V, et al. Clinical and phenotypic characterization of common variable immunodeficiency diagnosed in younger and older adults. J Clin Immunol. 2022. Aug;42(6):1270–1279. doi: 10.1007/s10875-022-01290-w PubMed DOI

Danieli MG, Mezzanotte C, Verga JU, et al. Common variable immunodeficiency in elderly patients: a long-term clinical experience. Biomedicines. 2022. Mar 9;10(3):635. doi: 10.3390/biomedicines10030635 PubMed DOI PMC

Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011. May;139(2):133–141. doi: 10.1016/j.clim.2011.01.006 PubMed DOI

Hartog NL, Williams KW, Abraham RS. “The state of the union”: current and future perspectives on patient-centric care for primary immunodeficiencies and immune dysregulatory diseases. Front Immunol. 2019;10:1783. doi: 10.3389/fimmu.2019.01783/full PubMed DOI PMC

Lamb CC, Wang Y. Physician characteristics that influence patient participation in the treatment of primary immunodeficiency. Patient Educ Couns. 2020. Nov;103(11):2280–2289. PubMed

Epstein RM, Street RL Jr.. Shared mind: communication, decision making, and autonomy in serious illness. Ann Fam Med. 2011. Sep;9(5):454–461. PubMed PMC

Cherin P, Pindi Sala T, Clerson P, et al. Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: a qualitative research study. Med (Baltimore). 2020. Feb;99(7):e19012. PubMed PMC

Gupta S, DeAngelo J, Melamed I, et al. Subcutaneous immunoglobulin 16.5% (Cutaquig®) in primary immunodeficiency disease: safety, tolerability, efficacy, and patient experience with enhanced infusion regimens. J Clin Immunol. 2023. Aug;43(6):1414–1425. PubMed PMC

Mallick R, Henderson T, Lahue BJ, et al. Subcutaneous immunoglobulin in primary immunodeficiency - impact of training and infusion characteristics on patient-reported outcomes. BMC Immunol. 2020. Aug 10;21(1):47. doi: 10.1186/s12865-020-00371-y PubMed DOI PMC

Gonzalez JM, Ballow M, Fairchild A, et al. Primary immune deficiency: patients’ preferences for replacement immunoglobulin therapy. Front Immunol. 2022;13:827305. doi: 10.3389/fimmu.2022.827305 PubMed DOI PMC

Anterasian C, Duong R, Gruenemeier P, et al. Quality of life differences for primary immunodeficiency patients on home SCIG versus IVIG. J Clin Immunol. 2019. Nov;39(8):814–822. doi: 10.1007/s10875-019-00705-5 PubMed DOI PMC

Wasserman RL. Personalized therapy: immunoglobulin replacement for antibody deficiency. Immunol Allergy Clin North Am. 2019. Feb;39(1):95–111. doi: 10.1016/j.iac.2018.08.001 PubMed DOI

Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc. 2016. Nov;37(6):426–431. doi: 10.2500/aap.2016.37.3987 PubMed DOI

Paterick TE, Patel N, Tajik AJ, et al. Improving health outcomes through patient education and partnerships with patients. Proc (Bayl Univ Med Cent). 2017. Jan;30(1):112–113. doi: 10.1080/08998280.2017.11929552 PubMed DOI PMC

Bhattad PB, Pacifico L. Empowering patients: promoting patient education and health literacy. Cureus. 2022. Jul;14(7):e27336. PubMed PMC

Immune Deficiency Foundation . Immunoglobulin replacement therapy. 2024. https://primaryimmune.org/understanding-primary-immunodeficiency/treatment/immunoglobulin-replacement-therapy

Immune Deficiency Foundation . Guide to ig therapy. 2024. https://primaryimmune.org/resources/print-material/idf-guide-to-ig-therapy

Allergy ASoCIa . Immunoglobulin replacement therapy. 2024. https://www.allergy.org.au/patients/immunodeficiencies/immunoglobulin-replacement-therapy

Anderson JT, Bonagura VR, Cowan J, et al. Safety and tolerability of subcutaneous IgPro20 at high infusion parameters in patients with primary immunodeficiency: findings form the pump-assisted administration cohorts of the HILO study. J Clin Immunol. 2021. Feb;41(2):458–469. doi: 10.1007/s10875-020-00912-5 PubMed DOI PMC

Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013. Feb;32(2):207–214. doi: 10.1377/hlthaff.2012.1061 PubMed DOI

Anderson-Smits C, Park M, Bell J, et al. Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022. Apr;14(5):373–387. doi: 10.2217/imt-2021-0265 PubMed DOI

Bienvenu B, Cozon G, Mataix Y, et al. Rapid push vs. pump-infused subcutaneous immunoglobulin treatments: a randomized crossover study of quality of life in primary immunodeficiency patients. J Clin Immunol. 2018;38(503–512):117–118. doi: 10.1007/s10875-018-0507-x PubMed DOI PMC

Lamb CC, Wang Y, Lyytinen K. Shared decision making: does a physician’s decision-making style affect patient participation in treatment choices for primary immunodeficiency? J Eval Clin Pract. 2019. Dec;25(6):1102–1110. doi: 10.1111/jep.13162 PubMed DOI PMC

Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6(7):853–869. PubMed

Chu LF, Utengen A, Kadry B, et al. “Nothing about us without us”-patient partnership in medical conferences. BMJ. 2016. Sep 14;354:i3883. doi: 10.1136/bmj.i3883 PubMed DOI

Kobayashi RH, Litzman J, Melamed I, et al. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. Clin Exp Immunol. 2022. Dec 15;210(2):91–103. doi: 10.1093/cei/uxac092 PubMed DOI PMC

Zhou T, Tegenge MA, Golding B, et al. Dosing strategy of immunoglobulin (IgG) replacement therapies in obese and overweight patients with primary immunodeficiency diseases (PIDDs): a meta‐analysis of clinical trials. J Clin Pharmacol. 2023;63:S110–S116. PubMed

Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol. 2008. Nov;122(5):1038–1039. doi: 10.1016/j.jaci.2008.08.012 PubMed DOI

Duff C, Ochoa D, Riley P, et al. Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site. J Infus Nurs. 2013. Nov;36(6):384–390. doi: 10.1097/NAN.0000000000000009 PubMed DOI

Duff C, Ballow M. Nuts and bolts of subcutaneous therapy. Immunol Allergy Clin North Am. 2020. Aug;40(3):527–537. doi: 10.1016/j.iac.2020.04.00 PubMed DOI

Sidhu JR, Pfister M, Edelman J. Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency. Biol Ther. 2014;4:41–55. doi: 10.1007/s13554-014-0018-0 PubMed DOI PMC

Badkar AG, Davis SP, LaBarre MJ. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Des Devel Ther. 2021;15:159–170. doi: 10.2147/DDDT.S287323 PubMed DOI PMC